JP2022520104A - Crispr/cas融合タンパク質およびシステム - Google Patents

Crispr/cas融合タンパク質およびシステム Download PDF

Info

Publication number
JP2022520104A
JP2022520104A JP2021547390A JP2021547390A JP2022520104A JP 2022520104 A JP2022520104 A JP 2022520104A JP 2021547390 A JP2021547390 A JP 2021547390A JP 2021547390 A JP2021547390 A JP 2021547390A JP 2022520104 A JP2022520104 A JP 2022520104A
Authority
JP
Japan
Prior art keywords
protein
cells
cell
fusion protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547390A
Other languages
English (en)
Japanese (ja)
Inventor
チェン,フーチアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma-Aldrich Co LLC
Original Assignee
Sigma-Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Aldrich Co LLC filed Critical Sigma-Aldrich Co LLC
Publication of JP2022520104A publication Critical patent/JP2022520104A/ja
Priority to JP2023122299A priority Critical patent/JP2023156365A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021547390A 2019-02-15 2020-02-13 Crispr/cas融合タンパク質およびシステム Pending JP2022520104A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023122299A JP2023156365A (ja) 2019-02-15 2023-07-27 Crispr/cas融合タンパク質およびシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806708P 2019-02-15 2019-02-15
US62/806,708 2019-02-15
PCT/US2020/018145 WO2020168102A1 (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023122299A Division JP2023156365A (ja) 2019-02-15 2023-07-27 Crispr/cas融合タンパク質およびシステム

Publications (1)

Publication Number Publication Date
JP2022520104A true JP2022520104A (ja) 2022-03-28

Family

ID=70166116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547390A Pending JP2022520104A (ja) 2019-02-15 2020-02-13 Crispr/cas融合タンパク質およびシステム
JP2023122299A Pending JP2023156365A (ja) 2019-02-15 2023-07-27 Crispr/cas融合タンパク質およびシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023122299A Pending JP2023156365A (ja) 2019-02-15 2023-07-27 Crispr/cas融合タンパク質およびシステム

Country Status (11)

Country Link
US (3) US10947517B2 (cg-RX-API-DMAC10.html)
EP (1) EP3924475A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022520104A (cg-RX-API-DMAC10.html)
KR (1) KR20210139271A (cg-RX-API-DMAC10.html)
CN (1) CN113728099A (cg-RX-API-DMAC10.html)
AU (2) AU2020221274B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016019A2 (cg-RX-API-DMAC10.html)
CA (1) CA3129835A1 (cg-RX-API-DMAC10.html)
IL (1) IL285300A (cg-RX-API-DMAC10.html)
SG (1) SG11202108812SA (cg-RX-API-DMAC10.html)
WO (1) WO2020168102A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11965184B2 (en) 2019-02-15 2024-04-23 Sigma-Aldrich Co. Llc CRISPR/Cas fusion proteins and systems

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
KR20260037664A (ko) * 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
CN116063546B (zh) * 2021-10-29 2026-01-16 中科辅酶医科技(深圳)有限公司 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用
US20230265405A1 (en) * 2022-02-22 2023-08-24 Massachusetts Institute Of Technology Engineered nucleases and methods of use thereof
AU2023232138A1 (en) * 2022-03-08 2024-09-26 Wake Forest University Health Sciences Compositions, systems and methods for eukaryotic gene editing
WO2025221793A1 (en) * 2024-04-16 2025-10-23 Monsanto Technology Llc Modified cas proteins for nuclear localization and editing activity in plants

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506886A (ja) * 2014-02-19 2017-03-16 バイオアシス テクノロジーズ インコーポレイテッド P97−ids融合タンパク質
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
JP2017532001A (ja) * 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
JP2018518969A (ja) * 2015-06-24 2018-07-19 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC 細胞周期依存性のゲノムの調節及び修飾

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) * 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3845655B1 (en) 2014-10-01 2025-01-01 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
JP6867689B2 (ja) * 2016-01-29 2021-05-12 国立大学法人東京工業大学 Cas9−gRNA複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN107579793A (zh) * 2016-07-04 2018-01-12 中兴通讯股份有限公司 一种通信网络设备间时间同步的优化方法、装置及设备
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11242513B2 (en) 2016-12-14 2022-02-08 Wageningen Universiteit Thermostable Cas9 nucleases
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CA3071769A1 (en) 2017-07-31 2019-02-07 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases
US11071791B2 (en) * 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
WO2019161290A1 (en) 2018-02-15 2019-08-22 Sigma-Aldrich Co. Llc Engineered cas9 systems for eukaryotic genome modification
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
SG11202108812SA (en) 2019-02-15 2021-09-29 Sigma Aldrich Co Llc Crispr/cas fusion proteins and systems

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532001A (ja) * 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
JP2017506886A (ja) * 2014-02-19 2017-03-16 バイオアシス テクノロジーズ インコーポレイテッド P97−ids融合タンパク質
JP2018518969A (ja) * 2015-06-24 2018-07-19 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC 細胞周期依存性のゲノムの調節及び修飾
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENBANK ACCESSION NUMBER: APD076536, [ONLINE], 28-NOV-2016, [検索日:2022年10月19日],<URL,HTTPS://, JPN6022044613, ISSN: 0005022628 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11965184B2 (en) 2019-02-15 2024-04-23 Sigma-Aldrich Co. Llc CRISPR/Cas fusion proteins and systems

Also Published As

Publication number Publication date
AU2024202275A1 (en) 2024-05-23
SG11202108812SA (en) 2021-09-29
US10947517B2 (en) 2021-03-16
AU2020221274B2 (en) 2024-02-08
JP2023156365A (ja) 2023-10-24
US11965184B2 (en) 2024-04-23
EP3924475A1 (en) 2021-12-22
US20200263155A1 (en) 2020-08-20
US20230287377A1 (en) 2023-09-14
CN113728099A (zh) 2021-11-30
WO2020168102A1 (en) 2020-08-20
BR112021016019A2 (pt) 2021-10-05
US20210163910A1 (en) 2021-06-03
AU2020221274A1 (en) 2021-08-26
KR20210139271A (ko) 2021-11-22
IL285300A (en) 2021-09-30
CA3129835A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP7469285B2 (ja) 標的化されたゲノム修飾を増強するためのヌクレオソーム相互作用タンパク質ドメインの使用
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたCas9システム
KR102458395B1 (ko) 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선
US20230287377A1 (en) Crispr/cas fusion proteins and systems
EP3138911A1 (en) Crispr-based genome modification and regulation
JP2020530992A (ja) Crispr/casアクチベーターシステムのための合成ガイドrna
KR102683424B1 (ko) 타우 응집과 관련된 유전적 취약성을 식별하기 위한 CRISPR/Cas 드랍아웃 스크리닝 플랫폼
JP7629673B2 (ja) ゲノム改変のための高忠実度SpCas9ヌクレアーゼ
HK40040051B (en) Engineered cas9 systems for eukaryotic genome modification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502